In a recent study published in Science Immunology, researchers evaluated immunoglobulin G (IgG) responses to coronavirus disease 2019 (COVID-19) messenger ribonucleic acid (mRNA) vaccinations. Study: ...

Inebilizumab-cdon, a monoclonal antibody that depletes B cells, reduces the risk for flares without showing any new safety signals in patients with immunoglobulin G4-related disease (IgG4-RD) who have ...

Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD). An international, ...

In a recent study posted to bioRxiv* preprint server, researchers in Germany assessed the differences in antigen-specific immunoglobulin G (IgG) subtypes between post-COVID syndrome (PCS) patients and ...

The FDA’s approval of inebilizumab has heralded a new era for patients with IgG4-related disease, while novel agents moving ...

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first ...

Dr. John H. Stone: A 45-year-old woman was referred to the rheumatology clinic of this hospital because of retroperitoneal fibrosis and the possibility of IgG4-related disease. Seven years before the ...

Arezou Khosroshahi, MD, professor of medicine at Emory University, discusses the importance of imaging to understand organ involvement and track changes over time. (2:32) Using univariate and ...

Detailed price information for Zenas Biopharma Inc (ZBIO-Q) from The Globe and Mail including charting and trades.

SACQ patients were more likely to have higher IgG4 levels at baseline and a higher prevalence of the proliferative subtype. Similar relapse rates were observed between SACQ and SQCQ (serologically ...

It is already known that patients with eosinophilic esophagitis have higher levels of immunoglobulin G4, and this study examined the relationship to specific foods and aeroallergens. A recent study ...